SEC Form 4 · accession 0001209191-17-066238
PORTOLA PHARMACEUTICALS INC · PTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry Ward Wolff
Director
Period of report
Dec 15, 2017
Accepted (ET)
Dec 18, 2017 · 8:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001269021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 5, 2017 | M | 12,000 | $5.30 | A | 12,000 | I | By Henry & Marian Wolff 1999 Revoc. Trust |
| Common StockF2,F1 | Dec 15, 2017 | S | 11,300 | $46.948 | D | 700 | I | By Henry & Marian Wolff 1999 Revoc. Trust |
| Common StockF3,F1 | Dec 15, 2017 | S | 700 | $47.7686 | D | 0 | I | By Henry & Marian Wolff 1999 Revoc. Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4,F1 | $5.30 | Oct 5, 2017 | M | 12,000 | D | Nov 15, 2007 | Nov 14, 2017 | Common Stock | 12,000 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 11, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.44 to $47.38, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.55 to $47.93, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- F4Mr. Wolff exercised these shares through a cash exercise and transferred the shares following the exercise into the Henry & Marian Wolff 1999 Revocable Trust for which Mr. Wolff is a trustee.